BioCentury
ARTICLE | Company News

AstraZeneca, 3SBio deal

October 17, 2016 7:00 AM UTC

AstraZeneca granted 3SBio exclusive, Chinese rights to commercialize diabetes drugs Byetta exenatide and its once-weekly form, Bydureon. AZ will receive $50 million up front and is eligible for up to ...